Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

859
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
859
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic Co-Delivery of siFGF2 and Doxorubicin via QTPlus Nanoparticles for Enhanced Breast Cancer Therapy.

Pharmaceutics·2026
Same author

Pseudomonas aeruginosa 3-oxo-C12HSL-induced apoptosis involves bitter taste receptor T2R14 and the mitochondrial calcium uniporter.

Cell calcium·2026
Same author

pH-regulated ''ON/OFF″ glucose oxidase nanoparticles for synergistic therapy and amplification of immunogenic cell death.

Free radical biology & medicine·2026
Same author

Cigarette Smoke Exposure Attenuates T2R-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma.

Head & neck·2026
Same author

Mechanisms of Mitochondrial Toxicity and Cytotoxicity Caused by Pseudomonas aeruginosa Pyocyanin in Human Nasal Epithelial Cells.

International forum of allergy & rhinology·2025
Same author

A dual-responsive metal-polyphenol nanomedicine based on targeting LAT1 via levodopa and ROS amplification for precise treatment of breast cancer.

Free radical biology & medicine·2025

Related Experiment Video

Updated: Apr 6, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

9.0K

Antisense Therapy for Cardiovascular Diseases.

M Ian Phillips1, Jessica Costales, Robert J Lee

  • 1Keck Graduate Institute, Claremont, CA, USA. ian_phillips@kgi.edu.

Current Pharmaceutical Design
|August 4, 2015
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotide therapy offers a precise genetic treatment for cardiac, metabolic, and muscular diseases with lasting effects and few side effects. This innovative approach targets conditions like hyperglycemia and hypercholesterolemia, with potential for treating muscular dystrophy and hypertension.

More Related Videos

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

62.3K
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
09:12

Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart

Published on: July 29, 2018

8.7K

Related Experiment Videos

Last Updated: Apr 6, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

9.0K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

62.3K
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
09:12

Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart

Published on: July 29, 2018

8.7K

Area of Science:

  • Biotechnology
  • Genetics
  • Pharmacology

Background:

  • Antisense oligonucleotide (ASO) therapy is an emerging precision medicine approach.
  • It targets diseases caused by specific genetic defects, offering a novel therapeutic strategy.
  • ASO therapy is noted for its relatively long duration and minimal side effects.

Purpose of the Study:

  • To review the applications of antisense oligonucleotide therapy in genetic diseases.
  • To highlight current and potential targets for ASO interventions.
  • To discuss the potential of ASO therapy in cardiovascular, metabolic, and muscular disorders.

Main Methods:

  • Review of existing literature and clinical applications of antisense oligonucleotide therapy.
  • Analysis of specific genetic targets and mechanisms of action for ASO drugs.
  • Examination of case studies and ongoing research in the field.

Main Results:

  • Antisense oligonucleotides have shown success in treating conditions like homozygous familial hypercholesterolemia with drugs like Kynamro (Mipomersen).
  • ASO therapy can be used to lower specific proteins or increase proteins inhibited by mutant exons.
  • Promising research includes exon skipping for Duchenne muscular dystrophy, potentially restoring muscle and cardiac function.

Conclusions:

  • Antisense oligonucleotide therapy is a versatile and effective precision medicine strategy.
  • Its application extends to a range of genetic disorders including cardiovascular, metabolic, and muscular diseases.
  • Further development holds significant promise for treating conditions such as hypertension, heart disease, and metabolic syndrome.